Indoleamine 2,3-dioxygenase (IDO) expression and malignant transformation in prostate cancer

被引：1
|
作者：
Provenzano, M.
Feder-Mengus, C.
Wyler, S.
Hudolin, T.
Ruszat, R.
Weber, W. P.
Sulser, T.
Bachmann, A.
Heberer, M.
Spagnoli, G. C.
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[2] ZLF, Basel, Switzerland
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5149
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [2] EXPRESSION OF INDOLEAMINE 2,3-DIOXYGENASE IN MALIGNANT MELANOMA
    Witkiewicz, A.
    Potoczek, M.
    Berger, A.
    Sato, T.
    Brody, J.
    Constantino, C.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2009, 36 (01) : 160 - 160
  • [3] Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer
    Ferreira, Janaina Mendes
    Delle, Humberto
    Camacho, Cleber Pinto
    Almeida, Robson Jose
    Reis, Sabrina Thalita
    Matos, Yves Silva Teles
    Lima, Amanda M. Ramos
    Leite, Katia Ramos Moreira
    Pontes-Junior, Jose
    Srougi, Miguel
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (08) : 1477 - 1482
  • [4] High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
    Feder-Mengus, Chantal
    Wyler, Stephen
    Hudolin, Tvrtko
    Ruszat, Robin
    Bubendorf, Lukas
    Chiarugi, Alberto
    Pittelli, Maria
    Weber, Walter P.
    Bachmann, Alexander
    Gasser, Thomas C.
    Sulser, Tullio
    Heberer, Michael
    Spagnoli, Giulio C.
    Provenzano, Maurizio
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (15) : 2266 - 2275
  • [5] Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer
    Janaina Mendes Ferreira
    Humberto Dellê
    Cleber Pinto Camacho
    Robson José Almeida
    Sabrina Thalita Reis
    Yves Silva Teles Matos
    Amanda M. Ramos Lima
    Kátia Ramos Moreira Leite
    José Pontes-Júnior
    Miguel Srougi
    International Urology and Nephrology, 2020, 52 : 1477 - 1482
  • [6] The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer
    Nishi, Masaaki
    Yoshikawa, Kozo
    Higashijima, Jun
    Tokunaga, Takuya
    Kashihara, Hideya
    Takasu, Chie
    Ishikawa, Daichi
    Wada, Yuma
    Shimada, Mitsuo
    ANTICANCER RESEARCH, 2018, 38 (06) : 3387 - 3392
  • [7] Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
    Guo, Yixuan
    Liu, Yu
    Wu, Wei
    Ling, Daishun
    Zhang, Qiao
    Zhao, Peng
    Hu, Xi
    BIOMATERIALS, 2021, 276
  • [8] Synthesis of indoleamine 2,3-dioxygenase (IDO) inhibitor
    Suzuki, Takafumi
    Yokoyama, Yuuaku
    Tsutumi, Katsuhiko
    Yamaguchi, Tomoyuki
    Takikawa, Osamu
    Okuno, Hiroaki
    JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC, 2010, 62 (01) : 114 - 115
  • [9] Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
    Selvan, Senthamil R.
    Dowling, John P.
    Kelly, William K.
    Lin, Jianqing
    CURRENT CANCER DRUG TARGETS, 2016, 16 (09) : 755 - 764
  • [10] The impact of indoleamine 2,3-dioxygenase (IDO) expression on stage III gastric cancer.
    Kashihara, Hideya
    Shimada, Mitsuo
    Yoshikawa, Kozo
    Higashijima, Jun
    Tokunaga, Takuya
    Nishi, Masaaki
    Takasu, Chie
    Ishikawa, Daichi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345